Creatine kinase (CK) is an important marker in the diagnosis of acute myocardial infarction (AMI). There are, however, other clinical conditions other than AMI which cause elevation of total CK activities in serum including: skeletal muscle trauma; alcohol intoxication; uncontrolled diabetes mellitus; convulsions; pulmonary emboli; rhabdomyolysis; and many others. I • 2 An increase in serum levels of CK has been demonstrated following administration of a wide variety of drugs." However, there is as yet no unifying hypothesis regarding the mechanism of this phenomenon. Steiness et al," have shown that certain medications such as diazepam cause an increase in serum CK activity as a result of muscle damage. The amount of CK liberated is determined both by the properties of the solution injected (active compound, vehicle, concentration, and volume) and by muscle factors such as local muscle blood flow, susceptibility of muscle to the damaging effect of the injection and local muscle binding to the medication.
However, the common clinical notion regarding intramuscular (1M) injections as a frequent cause of serum CK elevations leading to an erroneous diagnosis of AMI in patients who have been given an 1M injection for non-cardiac reasons has been challenged by Konicoff et al. s
We investigated serum CK elevation following a single 1M injection of medications commonly used in patients admitted to a medical ward.
SUBJECTS AND METHODS
Eighteen adult patients (nine men and nine women, aged 26-91 years) were studied. They Correspondence: Dr N Krivoy.
had been admitted to a medical ward for noncardiac reasons, and had baseline CK values within the reference range « 280 U/L), measured less than 24 h before the injection. None had clinical conditions known to produce elevation of serum CK on the day of the 1M injection. The study protocol was approved by the Hospital Ethical Committee. Each patient received a single 1M injection in the gluteal muscle of one of the following medications (numbers of patients in parentheses): haloperidol (4); papaverine (5); paraldehyde (6); hydralazine hydrochloride (1); promethazine hydrochloride (1); and methotrexate (1). No further 1M injections were given to the subjects for the next 36 h (patients who required further 1M injections in this period were excluded from the study). Simultaneous myocardial injury was excluded in all patients by twice daily clinical evaluation and electrocardiographic study.
Serum CK activity was measured before and 12 24 and 36 h after the injection. Enzyme ac~ivity was measured using the Technicon Chern 1 (Technicon Instruments, Tarrytown, NJ, USA) assay by the manufacturer's recommended method, at 37°C. The reference range of CK activity for this method is 50-280 U/L.
Statistical analysis was performed using the nonparametric Mann-Whitney Utest to compa~e the changes across time, significance was established when P<0·05.
RESULTS
The dose, volume, and the CK activity after each medication are shown in Table 1 . The osmolarity and pH of the injected medications were, paraldehyde 9000 mOsm/L, pH 3· 3; haloperidol 70 mOsm/L, pH 3 ,4; papaverine 60 mOsm/L, pH 3· 4; hydralazine 70 mOsm/L, pH 4' 3 and promethazine 296 mOsm/L, pH 5· 8, respectively. The change in CK activity was observed mainly in the group who received paraldehyde, where all six patients were injected with a volume> 5 mL. One of the four patients who received haloperidol had an elevated total CK concentration ( Table 1) .
This patient received 4 mL, while the others, who were injected with only 2 mL, did not show a significant elevation in their CK activity across time after the 1M injection.
CONCLUSION
Our data showed a significant increase from base line values in total serum CK activity across time (up to 36 h) after the 1M injection of paraldehyde in all six patients and only one of four subjects injected with haloperidol. The other medications papaverine, hydralazine, promethazine and methotrexate) did not affect the CK serum concentration.
Young! states that neither paraldehyde nor haloperidol cause any effect on the analytical technique of CK determination. The same source does not include paraldehyde or haloperidol as medications which can cause an increase in CK activity when delivered using the 1M route.
Previous studies have demonstrated elevations of serum CK activity after the 1M injections of several medications, all of which were administered in volumes less than 2 mL. 4, 6 Steiness et al." demonstrated the highest CK activity in rabbits, less in pigs and only minor increases in humans when 2 mL of a medication was injected 1M, and they ascribed this to a difference in total volume of distribution of the CK released from the damaged muscle fibres. Sidell et al,' suggested that the diluent and/or the osmolarity and pH of the injected medication may make a significant contribution to the increased CK observed after 1M injection, From our results, is possible to assume that the injected volume and the high osmolarity of paraldehyde are involved in the increased serum CK activity as measured after a single 1M injection. The volume effect is certainly connected to the forced introduction of the drug solution, which has also high osmolarity, into a relatively dense muscle mass resulting in transient local necrosis."
The other medications, except for one out of four haloperidol treated patients (all given in a lower volume and having lower osmolarity) did not result in a significant increase in the serum enzyme activity following injection. In addition, the pH does not seem to be a factor in CK elevation since all the drugs were equally acidic.
